Autolus Therapeutics
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 471
- Market Cap
- $1B
- Website
- http://www.autolus.com
- Introduction
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
FDA approves new CAR-T competitor to Gilead's Tecartus
FDA approves Autolus Therapeutics' Aucatzyl, a CAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukemia, priced at $525,000, 11% higher than Gilead's Tecartus. Aucatzyl aims to reduce side effects and is the first CAR-T approved without a risk mitigation plan, with 63% complete remission rate in clinical trial.
Risk of aspiration during surgery added to GLP-1 drug labels
Changes in Washington may affect healthcare, with potential tweaks to Medicare drug price negotiation and increased anti-pharma rhetoric under Trump. GLP-1 drugs like Ozempic and Wegovy now warn of aspiration risk during surgery. RFK Jr.'s influence could lead to looser oversight of supplements. Skorney and Zohar discuss Trump's impact on FDA and biotech. RFK Jr. crowdsources health-related government nominees.
FDA approves Autolus' Aucatzyl to treat acute lymphoblastic leukaemia
FDA approves Autolus Therapeutics’ Aucatzyl for adult relapsed or refractory B-cell precursor ALL, the first CAR-T therapy without a risk evaluation mitigation strategy. Supported by FELIX trial data showing 42% complete remission within three months, with median duration of 14.1 months.
Syncona's Autolus wins FDA approval for aggressive leukaemia therapy
Syncona Ltd announced FDA approval for Autolus Therapeutics' Aucatzyl, a treatment for adult relapsed acute lymphoblastic leukaemia, based on the Felix trial results showing 63% complete remission.
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel)
FDA approves AUCATZYL, a CAR T therapy for adult r/r B-ALL, based on FELIX trial results. AUCATZYL showed 63% OCR in efficacy evaluable patients, with low CRS and no REMS required. Safety concerns include CRS, neurologic toxicities, and secondary malignancies.
Syncona's Autolus gets FDA approval for leukaemia treatment
Syncona's portfolio company Autolus Therapeutics received FDA approval for Aucatzyl (obe-cel), a CAR T-cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL). The approval was based on the FELIX clinical trial data, showing a strong safety profile and 63% complete remission rate among evaluable patients.
Autolus Receives FDA Approval For AUCATZYL In Adults With Relapsed/Refractory B-ALL
Syncona Ltd's portfolio company Autolus Therapeutics announced FDA approval for AUCATZYL (obe-cel) for treating adult patients with relapsed or refractory B-cell precursor acute.
Syncona's Autolus Gains FDA Approval for Leukemia Therapy
Syncona's Autolus Therapeutics received FDA approval for AUCATZYL®, a CAR T-cell therapy for relapsed or refractory B-cell precursor acute lymphoblastic leukemia, based on FELIX trial results.
© Copyright 2025. All Rights Reserved by MedPath